Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. BCPT policy for experimental and clinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Polypharmacy in schizophrenia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Synaptic processes and immune-related pathways implicated in Tourette syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Are All Psychotic-Like Experiences Really "Psychotic"? Response to McLawhorn and Jackson

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Somatiske årsager til akut opståede psykiatriske tilstande hos børn og unge

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

This study investigated the influence of variations in the carboxylesterase 1 gene (CES1) on the pharmacokinetics of enalapril. Forty-three healthy, Danish, Caucasian volunteers representing different pre-defined genotypes each received 10 mg of enalapril. At specified time-points, plasma concentrations of enalapril and the active metabolite enalaprilat were measured. The volunteers were divided into six different groups according to their genetic profile of CES1: group 1 (control group, n = 16) with two CES1 copies without non-synonymous SNPs in the exons; group 2 (n = 5) with four copies of CES1; group 3 (n = 6) harbouring the G143E polymorphism; group 4 (n = 2) with three CES1 copies and increased transcriptional activity of the duplication (CES1A2); group 5 (n = 4) harbouring the CES1A1c variant; and group 6 (n = 10) with three CES1 copies and the common promoter with low transcriptional activity of the duplication. The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively). The terminal half-life of enalaprilat was significantly longer in group 6 compared with the control group (26.7 hr versus 12.7 hr, respectively). However, this was not considered clinically relevant. In conclusion, none of the selected variations of CES1 had a clinically relevant impact on the metabolism of enalapril.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
ISSN1742-7843
DOI
StatusUdgivet - jul. 2017

ID: 51521057